Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by ...

People who talk in their sleep may be at greater risk of stroke, according to a study of 8,001 Chinese adults. The risk was ...

Growing numbers of people in Ireland are taking the risk of going online to illegally secure supplies of weight-loss jabs ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.

There may be properties of anti-obesity medications that lead to reduced use. For example, naltrexone decreases cravings for alcohol and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...

Insurance business units report positive operating performance while facing mounting industry-wide cost pressures Allegheny Health Network reports 9% total revenue ...

When Ozempic and Wegovy don’t work, genetic differences, medical conditions, or side effects could be to blame. Is it normal, ...

Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.